The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
An anti-human interleukin 5 receptor (hIL-5R) humanized immunoglobulin G1 (IgG1) and an anti-CD20 chimeric IgG1 produced by rat hybridoma YB2/0 cell lines showed more than 50-fold higher antibody-dependent cellular cytotoxicity (ADCC) using purified human peripheral blood mononuclear cells as effector than those produced by Chinese hamster ovary (CHO) cell lines. Monosaccharide composition and oligosaccharide profiling analysis showed that low fucose (Fuc) content of complex-type oligosaccharides was characteristic in YB2/0-produced IgG1s compared with high Fuc content of CHO-produced IgG1s. YB2/0-produced anti-hIL-5R IgG1 was subjected to Lens culinaris aggulutin affinity column and fractionated based on the contents of Fuc. The lower Fuc IgG1 had higher ADCC than the IgG1 before separation. In contrast, the content of bisecting GlcNAc of the IgG1 affected ADCC much less than that of Fuc. In addition, the correlation between Gal and ADCC was not observed. When the combined effect of Fuc and bisecting GlcNAc was examined in anti-CD20 IgG1, only a severalfold increase of ADCC was observed by the addition of GlcNAc to highly fucosylated IgG1. Quantitative PCR analysis indicated that YB2/0 cells had lower expression level of FUT8 mRNA, which codes alpha1,6-fucosyltransferase, than CHO cells. Overexpression of FUT8 mRNA in YB2/0 cells led to an increase of fucosylated oligosaccharides and decrease of ADCC of the IgG1. These results indicate that the lack of fucosylation of IgG1 has the most critical role in enhancement of ADCC, although several reports have suggested the importance of Gal or bisecting GlcNAc and provide important information to produce the effective therapeutic antibody.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is ideal as increases in fucosylation have been correlated with decreased ADCC activity and decreased FcγRIIIa and FcγRIIb binding affinity. 40 , 41 , 42 , 43”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“lower cell specific productivity has been shown to allow for more mature glycoforms, including G2F. 42”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“Enriching the abundance of mAb N-glycoforms with β1,4-linked galactose (Gal) can also be desirable as it has been shown to enhance complement-dependent cytotoxicity (CDC), another mechanism for the selective depletion of tumour cells by Fc activation of the complement pathway [16–21].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“The addition of bisecting β1,4-linked N-acetylglucosamine (GlcNAc) by endogenous or recombinant N-acetylglucosaminyltransferase III (GnT-III in YB2/0 and CHO cells respectively) or via in vitro glycan remodelling has also been linked to increased ADCC in IgGs, albeit to a lesser extent than afucosylation [15–17].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“It was reported that afucosylated Fc domain glycans of human IgG1 could enhance the binding to FcγRIIIa subtype receptors of natural killer cells (Shields et al., 2002;Shinkawa et al., 2003;Niwa et al., 2005;Iida et al., 2006;Subedi and Barb, 2016).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Shinkawa et al., 2003
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
Refined Structure of an Intact IgG2a Monoclonal Antibody,
Harris, L. J., Larson, S. B., Hasel, K. W., & McPherson, A. (1997) · Biochemistry · doi:10.1021/bi962514+ · Cited by 451
Crystallographic structure of an intact IgG1 monoclonal antibody 1 1Edited by I. A. Wilson
Harris, L. J., Skaletsky, E., & McPherson, A. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1508 · Cited by 440
Research works printed but not linked: 2
- Rademacher, 1986, Biochem. Soc. Symp., 51, 131
- Kumpel, 1994, Hum. Antib. Hybrid., 5, 143
Cited by
Items 801–900 of 1,000
Molecular mechanisms in allergy and clinical immunology
Shearer, W. T., Rosenwasser, L. J., Bochner, B. S., Gern, J. E., Rosenthal, L. A., Sorkness, R. L., & Lemanske, R. F. (2005) · Cited by 19
Tomida, S., Nagae, M., & Kizuka, Y. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102676 · Cited by 19
“In addition, removing core fucose from IgG1 N-glycan causes a dramatic rise in antibody-dependent cellular cytotoxicity (18), which has already been clinically used to functionally modify antibody drugs.”
BackgroundCrescioli, S., Jatiani, S., & Moise, L. (2025) · mAbs · doi:10.1080/19420862.2025.2453515 · Cited by 18
Quantifying antibody binding: techniques and therapeutic implications
Lodge, J., Kajtar, L., Duxbury, R., Hall, D., Burley, G. A., Cordy, J. M., Yates, J. W. T., & Rattray, Z. (2025) · mAbs · doi:10.1080/19420862.2025.2459795 · Cited by 27
Hocheffiziente Synthese von multiantennären “bisected” N‐Glycanen über Imidate
Mönnich, M., Eller, S., Karagiannis, T., Perkams, L., Luber, T., Ott, D., Niemietz, M., Hoffman, J., Walcher, J., Berger, L., et al. (2016) · Angewandte Chemie · doi:10.1002/ange.201604190 · Cited by 18
An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology
Nikolov, N. P., & Shapiro, M. A. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.204 · Cited by 20
Zaytseva, O. O., Sharapov, S., Perola, M., Esko, T., Landini, A., Hayward, C., Wilson, J. F., Lauc, G., Aulchenko, Y. S., Klarić, L., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab335 · Cited by 20
“Nevertheless, the functional role of bisected IgG glycans in these processes is unclear (56).”
Yanaka, S., Yagi, H., Yogo, R., Onitsuka, M., & Kato, K. (2022) · Journal of Biomolecular NMR · doi:10.1007/s10858-021-00387-5 · Cited by 17
Takei, J., Suzuki, H., Asano, T., Tanaka, T., Kaneko, M. K., & Kato, Y. (2022) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2021.0064 · Cited by 18
“Mogamulizumab binds to Fcg receptor IIIa on natural killer cells and exerts potent antibody-dependent cellular cytotoxicity (ADCC) against the CCR4 cells.((9,10)) Mogamulizumab was first approved in Japan for ATLL therapy.”
Identification and validation of IgG N-glycosylation biomarkers of esophageal carcinoma
Pan, H., Wu, Z., Zhang, H., Zhang, J., Liu, Y., Li, Z., Feng, W., Wang, G., Liu, Y., Zhao, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.981861 · Cited by 17
Wang, F., Wang, R., Zhong, D., Zhao, P., & Xia, Q. (2023) · Insect Science · doi:10.1111/1744-7917.13289 · Cited by 17
“In addition, a small proportion of α - 1,6-fucosylated glycans reported to enhance the binding of mAbs to FcrRIIIa and the ADCC activity (Shinkawa et al. , 2003), but not the α -1,3-fucosylated glycans which causes immunogenic reactions (Altmann et al. , 1999), was detected in the rhEcSOD produced…”
Emerging Antibody-based Products
Whaley, K. J., Morton, J., Hume, S., Hiatt, E., Bratcher, B., Klimyuk, V. I., Hiatt, A., Pauly, M. H., & Zeitlin, L. (2012) · Current topics in microbiology and immunology · doi:10.1007/82_2012_240 · Cited by 18
Activating and inhibitory Fcγ receptors in immunotherapy: being the actor or being the target
Abès, R., Dutertre, C., Agnelli, L., & Teillaud, J. (2009) · Expert Review of Clinical Immunology · doi:10.1586/eci.09.57 · Cited by 22
Roy, G., Martin, T., Barnes, A. S., Wang, J., Jimenez, R. B., Rice, M., Li, L., Feng, H., Zhang, S. J., Chaerkady, R., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1433975 · Cited by 19
Manabe, S., Yamaguchi, Y., Abe, J., Matsumoto, K., & Ito, Y. (2018) · Royal Society Open Science · doi:10.1098/rsos.171521 · Cited by 18
“influences antibody effector functions, stability, and pharmacokinetics/pharmacodynamics [17,18].”
BackgroundMogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma
Ureshino, H., Kamachi, K., & Kimura, S. H. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.03.004 · Cited by 23
Kobayashi, H., Okada, K., Tokuda, S., Kanao, E., Masuda, Y., Naito, T., Takaya, H., Yan, M., Kubo, T., & Otsuka, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-70904-3 · Cited by 19
Liu, T., Han, J., Zhang, R., Tang, Z., Yi, G., Gong, W., Wan, L., Hu, Q., Teng, J., Liu, H., et al. (2021) · Rheumatology · doi:10.1093/rheumatology/keab416 · Cited by 20
Gong, Y., Wolterink, R. G. J. K., Gulaia, V. S., Cloosen, S., Ehlers, F. A. I., Wieten, L., Graus, Y., Bos, G. M. J., & Germeraad, W. T. V. (2021) · Cancers · doi:10.3390/cancers13112579 · Cited by 20
“[10] More specifically, removal of fucose on the N-glycan of the Fc tail has been shown to increase Fc-binding affinity to the FcγRIIIa, leading to enhanced ADCC [11,12].”
BackgroundNext-generation optimized biotherapeutics — A review and preclinical study
Ueda, T. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.06.008 · Cited by 20
Engineering broadly neutralizing antibodies for HIV prevention and therapy
Hua, C. K., & Ackerman, M. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.013 · Cited by 18
Implementation of Glycan Remodeling to Plant-Made Therapeutic Antibodies
Bennett, L. D., Yang, Q., Berquist, B. R., Giddens, J. P., Ren, Z., Kommineni, V., Murray, R. C., White, E. L., Holtz, B. R., Wang, L., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020421 · Cited by 19
Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review
Fernández-Guarino, M., Ortiz-Romero, P. L., Gallardo, F., & Llamas‐Velasco, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042203 · Cited by 17
“Shinkawa et al. have reported that a fucose-containing sugar chain in the Fc region plays a pivotal role in influencing ADCC activity, demonstrating that defucosylated IgG1 enhances ADCC activity more than 50-fold [13].”
BackgroundA metabolic inhibitor blocks cellular fucosylation and enables production of afucosylated antibodies
Gilormini, P., Thota, V. N., Fers-Lidou, A., Ashmus, R. A., Nodwell, M. B., Brockerman, J., Kuo, C., Wang, Y., Gray, T. E., Nitin, N., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314026121 · Cited by 19
Interaction of cell culture process parameters for modulating mAb afucosylation
Dang, A. N., Mun, M., Rose, C. M., Ahyow, P., Meier, A., Sandoval, W. N., & Yuk, I. H. Y. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.26908 · Cited by 19
“For some mAbs, afucosylation (i.e., the lack of core fucose) can dramatically enhance their potency through antibody‐dependent cellular cytotoxicity (ADCC) activity (Ferrara et al., 2011; Shields et al., 2002; Shinkawa et al., 2003; Thomann, Reckermann, Reusch, Prasser, & Tejada, 2016).”
BackgroundVector-related stratagems for enhanced monoclonal antibody production in mammalian cells
Gupta, K., Parasnis, M. S., Jain, R. D., & Dandekar, P. P. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107415 · Cited by 18
Kuhns, S. T., Shu, J., Xiang, C. D., Guzman, R. D., Zhang, Q., Bretzlaff, W., Miscalichi, N., Kalenian, K., & Joubert, M. K. (2020) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2020.04.017 · Cited by 23
Nakagawa, T., Natsume, A., Satoh, M., & Niwa, R. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.10.029 · Cited by 17
Self-citationTong, X., Li, T., Li, C., & Wang, L. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00719 · Cited by 18
Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
Bobrowicz, M., Zagożdżon, R., Domagała, J., Vasconcelos‐Berg, R., Guenova, E., & Winiarska, M. (2019) · Cancers · doi:10.3390/cancers11101420 · Cited by 17
“ADCC—antibody-dependent cell-mediated cytotoxicity, APC—antigen presenting cell, CSCC—cutaneous squamous cell carcinoma, CTCL—cutaneous T-cell lymphoma, NA—non-applicable, MCC—Merkel-cell carcinoma, MM—malignant melanoma.”
BackgroundInfluentialGurjar, S. A., Wheeler, J. X., Wadhwa, M., Thorpe, R., Kimber, I., Derrick, J. P., Dearman, R. J., & Metcalfe, C. L. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010637 · Cited by 18
“For example, the absence of fucose within the N-linked glycan present on the Fc is well documented to enhance antibody-dependent cellular cytotoxicity (ADCC) activity (33,34).”
Bhargava, R., Upadhyay, R., Zhao, C., Katakam, P. V. G., Wenderfer, S. E., Chen, J., He, H., Cummings, R. D., Tsokos, M., & Tsokos, G. C. (2025) · Arthritis & Rheumatology · doi:10.1002/art.43200 · Cited by 18
“17 The combination of a terminal sialic acid with galactose in the penultimate position has been reported to be associated with decreased in fl ammation, a reduction in the binding of the antibody to its Fc receptor, and the regulation of other cell interactions.”
Kim, Y.-S., Hwang, J., Lee, S. G., Jo, H. Y., Oh, M. J., Liyanage, N. M., Je, J.-G., An, H. J., & Jeon, Y. (2022) · Food & Function · doi:10.1039/d1fo03946f · Cited by 16
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
Wines, B. D., Kurtovic, L., Trist, H. M., Esparon, S. E., López, E., Chappin, K., Chan, L., Mordant, F. L., Lee, W. S., Gherardin, N. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.889372 · Cited by 16
“Lastly, FcgR potency of trACE2-Fc was improved by modifying the Fc glycan (82) to enhance FcgRIII binding (92).”
BackgroundA fluorogenic probe for core-fucosylated glycan-preferred ENGase
Ishii, N., Muto, H., Nagata, M., Sano, K., Sato, I., Iino, K., Matsuzaki, Y., Katoh, T., Yamamoto, K., & Matsuo, I. (2022) · Carbohydrate Research · doi:10.1016/j.carres.2022.108724 · Cited by 16
Kanto, N., Ohkawa, Y., Kitano, M., Maeda, K., Shiida, M., Ono, T., Ota, F., Kizuka, Y., Kunimasa, K., Nishino, K., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105365 · Cited by 17
“The deletion of the core fucose of IgG, i.e., an increase in acore fucosylated (noncore fucosylated) IgG, dramatically enhances antibody-dependent cellular cytotoxicity by strengthening its af fi nity for the Fc γ IIIa receptor that is expressed on myeloid cells and natural killer cells (30).”
BackgroundImmunocytokines with target cell–restricted IL-15 activity for treatment of B cell malignancies
Zekri, L., Hagelstein, I., Märklin, M., Klimovich, B., Christie, M., Lindner, C., Kämereit, S., Prakash, N., Müller, S., Stotz, S., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adh1988 · Cited by 16
Senini, I., Tengattini, S., Rinaldi, F., Massolini, G., Gstöttner, C., Reusch, D., Donini, M., Marusic, C., van Veelen, P. A., Domínguez‐Vega, E., et al. (2024) · Communications Chemistry · doi:10.1038/s42004-024-01297-x · Cited by 24
Anti-rhesus D prophylaxis in pregnant women is based on sialylated IgG antibodies
Winkler, A., Berger, M., & Ehlers, M. (2013) · F1000Research · doi:10.12688/f1000research.2-169.v1 · Cited by 18
Costa, A. R., Withers, J., Rodrigues, M. E., McLoughlin, N., Henriques, M., Oliveira, R., Rudd, P. M., & Azeredo, J. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-25 · Cited by 18
Phase I to III Trials of Anti–B Cell Therapy in Non–Hodgkin's Lymphoma
Martin, P., Furman, R. R., Coleman, M., & Leonard, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1085 · Cited by 16
Zhang, A., Tsang, V. L., Markely, L. R. A., Kurt, L., Huang, Y., Prajapati, S., & Kshirsagar, R. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.25995 · Cited by 18
“…complex-type oligosaccharides was characteristic in rat hybridoma YB2/0-produced IgG1s compared with high fucose content of CHO-produced IgG1s due to lower expression levels of FUT8 mRNA, which codes a1,6-fucosyltransferase, the key enzyme in the fucosylation pathway (Shinkawa et al., 2003) (Fig.”
BackgroundPace, D. L., Lewis, N. E., Wu, T. J.-T., Gillespie, R., Dan, L., Velayudhan, J., Rohrbach, A. S., & Connell‐Crowley, L. (2016) · Biotechnology Progress · doi:10.1002/btpr.2300 · Cited by 18
Nakamura, H., Kiyoshi, M., Anraku, M., Hashii, N., Oda‐Ueda, N., Ueda, T., & Ohkuri, T. (2020) · The Journal of Biochemistry · doi:10.1093/jb/mvaa116 · Cited by 16
Štambuk, J., Vučković, F., Habazin, S., Hanić, M., Novokmet, M., Nikolaus, S., Tran, F., Schreiber, S., Franke, A., Rosenstiel, P. C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158473 · Cited by 18
“Sweeping changes in IgG inflammatory functions can be observed with various IgG glycan patterns [17,18].”
BackgroundGaza‐Bulseco, G., Hickman, K., Sinicropi-Yao, S. L., Hurkmans, K., Chumsae, C. M., & Liu, H. (2009) · Journal of Chromatography A · doi:10.1016/j.chroma.2009.01.014 · Cited by 18
Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice
Gallagher, S., Turman, S., Yusuf, I., Akhgar, A., Wu, Y., Roskos, L. K., Herbst, R., & Wang, Y. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.04.035 · Cited by 18
Caminati, M., Bagnasco, D., Vaia, R., & Senna, G. (2019) · Biologics · doi:10.2147/btt.s157183 · Cited by 16
“In vitro studies have demonstrated that basophils constitutively express IL-5Rα but do not require IL-5 for their survival.(16) Benralizumab potently induces basophil apoptosis in vitro, even though no significant data are available for in-vivo studies due to median low count of basophils at baseline in patients recru…”
BackgroundEfficient Chemoenzymatic Synthesis of N‐Glycans with a β1,4‐Galactosylated Bisecting GlcNAc Motif
Weiss, M., Ott, D., Karagiannis, T., Weishaupt, M., Niemietz, M., Eller, S., Lott, M., Martínez‐Orts, M., Canales, Á., Razi, N., et al. (2020) · ChemBioChem · doi:10.1002/cbic.202000268 · Cited by 16
Wang, Y., Santos, M., & Guttman, A. (2013) · Journal of Separation Science · doi:10.1002/jssc.201300528 · Cited by 16
Novel and Engineered Anti–B-Cell Monoclonal Antibodies for Non-Hodgkin’s Lymphoma
Martin, P., Furman, R. R., Ruan, J., Elstrom, R., Barrientos, J. C., Niesvizky, R., Coleman, M., & Leonard, J. P. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.02.007 · Cited by 16
Yamaguchi, Y., Takahashi, N., & Kato, K. (2007) · Elsevier eBooks · doi:10.1016/b978-044451967-2/00072-6 · Cited by 19
8thAnnual European Antibody Congress 2012: November 27–28, 2012, Geneva, Switzerland
Beck, A., Carter, P. J., Gerber, H., Lugovskoy, A. A., Wurch, T., Junutula, J. R., Kontermann, R. E., & Mabry, R. (2013) · mAbs · doi:10.4161/mabs.24105 · Cited by 17
Increased expression of SSEA-4 on TKI-resistant non–small cell lung cancer with EGFR-T790M mutation
Chen, N.-Y., Lin, C.-W., Lai, T.-Y., Wu, C., Liao, P.-C., Hsu, T.-L., & Wong, C. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2313397121 · Cited by 18
Krishna, S., Jung, S. T., & Lee, E. Y. (2024) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2024.2342969 · Cited by 14
“The core of the oligosaccharide moiety is a heptasaccharide with variable incorporation of fucose, galactose, bisecting N -acetylglucosamine, and sialic acid, and in which the sialylation (mono-or disialyla-tion) is limited to 10% [52–57].”
Yamamoto, H., Takematsu, H., Fujinawa, R., Naito, Y., Okuno, Y., Tsujimoto, G., Suzuki, A., & Kozutsumi, Y. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001232 · Cited by 16
“. The presence of a core Fuc in the N-glycan of the Fc region of IgG severely represses the antibody-dependent cellular cytotoxicity activity of the antibody”
BackgroundEnhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells
Anand, S. P., Ding, S., Tolbert, W. D., Prévost, J., Richard, J., Gil, H. M., Gendron‐Lepage, G., Cheung, W.-F., Wang, H., Pastora, R., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00796-21 · Cited by 16
“Consequently, afucosylated MAbs can mediate significantly stronger ADCC responses (28, 67).”
BackgroundThe War Is on: The Immune System against Glioblastoma—How Can NK Cells Drive This Battle?
da Silva, L. H. R., Catharino, L. C. C., da Silva, V. J., Evangelista, G. C. M., & Barbuto, J. A. M. (2022) · Biomedicines · doi:10.3390/biomedicines10020400 · Cited by 19
Tomita, U., Yamaguchi, S., Sugimoto, Y., Takamori, S., & Nagamune, T. (2012) · Pharmaceuticals · doi:10.3390/ph5050405 · Cited by 15
Glycosylation of random IgG distinguishes seropositive and seronegative rheumatoid arthritis
Magorivska, I., Döncző, B., Dumych, T. I., Karmash, A., Boichuk, M. O., Hychka, К. М., Mihalj, M., Szabó, M., Csánky, E., Rech, J., et al. (2018) · Autoimmunity · doi:10.1080/08916934.2018.1468886 · Cited by 15
“The exposure of fucose and of branching GlcNAc is greatly influencing the ADCC of Ab preparation, and thus a main target during the design of efficient monoclonal Ab [25].”
BackgroundInfluentialDuan, C., Fukuda, T., Isaji, T., Qi, F., Yang, J. A., Wang, Y., Takahashi, S., & Gu, J. (2020) · The FASEB Journal · doi:10.1096/fj.201902313rr · Cited by 16
Ihara, H., Okada, T., Taniguchi, N., & Ikeda, Y. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129596 · Cited by 16
Lo, K.-M., Léger, O. J. P., & Hock, B. M. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.aid-0007-12 · Cited by 14
“Indeed, the enhancement effect of bisecting GlcNAc was only observed in highly fucosylated IgG1, which has low ADCC activity (29).”
BackgroundEvaluation of Effects of Fc Domain High-Mannose Glycan on Antibody Stability
Lu, Y., Westland, K., Ma, Y.-H., & Gadgil, H. S. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23284 · Cited by 15
Manabe, S., Iwamoto, S., Nagatoishi, S., Hoshinoo, A., Mitani, A., Sumiyoshi, W., Kinoshita, T., Yamaguchi, Y., & Tsumoto, K. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c06558 · Cited by 14
Fc-Linked IgG N-Glycosylation in FcγR Knock-Out Mice
Zaytseva, O. O., Seeling, M., Krištić, J., Lauc, G., Pezer, M., & Nimmerjahn, F. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00067 · Cited by 14
“…with the fact that the two glycan moieties attached to each Fc domain can vary due to asymmetric glycosylation, this results in several hundred possible different IgG Fc glycosylation variants (Shields et al., 2002; Shinkawa et al., 2003; Arnold et al., 2007; Kao et al., 2015; Quast et al., 2015).”
BackgroundThe Importance of Glycosylation in COVID-19 Infection
Pribić, T., Lauc, G., & Trbojević‐Akmačić, I. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-70115-4_12 · Cited by 17
Zlatina, K., & Galuska, S. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753294 · Cited by 19
“Moreover, defucosylated IgGs have a higher affinity to FcgRIIIa, resulting in improved effector functions (18, 20, 21) (Figure 5A).”
BackgroundAsano, T., Suzuki, H., Li, G., Ohishi, T., Kawada, M., Yoshikawa, T., Tanaka, T., Kaneko, M. K., & Kato, Y. (2022) · Antibodies · doi:10.3390/antib11040074 · Cited by 16
Polyfunctional antibodies: a path towards precision vaccines for vulnerable populations
Purcell, R. A., Theisen, R. M., Arnold, K. B., Chung, A. W., & Selva, K. J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183727 · Cited by 18
A Neutralizing Antibody Assay Based on a Reporter of Antibody-Dependent Cell-Mediated Cytotoxicity
Wu, Y., Li, J. J., Kim, H., Liu, X., Liu, W., Akhgar, A., Bowen, M. A., Spitz, S. M., Jiang, X., Roskos, L. K., et al. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9798-5 · Cited by 15
Sarantopoulos, J., Mita, M. M., Birrer, M. J., Cranmer, L. D., Campos, L. T., Zhang, X., Bristow, P., Kaito, H., Strout, V., & Camacho, L. H. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0394-5 · Cited by 14
Tsukimura, W., Kurogochi, M., Mori, M., Osumi, K., Matsuda, A., Takegawa, K., Furukawa, K., & Shirai, T. (2017) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2017.1394813 · Cited by 19
Falconer, D. J., & Barb, A. W. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192123 · Cited by 19
A novel glycosylated anti-CD20 monoclonal antibody from transgenic cattle
Zhang, R., Tang, C., Guo, H., Tang, B., Hou, S., Zhao, L., Wang, J., Ding, F., Zhao, J., Wang, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31417-2 · Cited by 17
Li, C., Li, T., & Wang, L. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8648-4_19 · Cited by 14
Glycosylation of Anti-Thyroglobulin IgG1 and IgG4 Subclasses in Thyroid Diseases
Li, Y., Zhao, C., Zhao, K., Yu, N., Li, Y., Yu, Y., Zhang, Y., Song, Z., Huang, Y., Lu, G., et al. (2020) · European Thyroid Journal · doi:10.1159/000507699 · Cited by 17
Kavur, M. M., Lauc, G., & Pezer, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819475-1.00086-9 · Cited by 18
IgG N-glycosylation from Patients with Pemphigus Treated with Rituximab
Font, G., Walet-Balieu, M.-L., Petit, M. A., Burel, C., Maho‐Vaillant, M., Hébert, V., Chan, P., Fréret, M., Boyer, O., Joly, P., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10081774 · Cited by 14
“Indeed, fu ‐ cosylation induces a 100 ‐ fold decrease in the affinity of IgG for the Fc γ RIIIA, thus avoid ‐ ing an excessive ADCC response [33–36].”
BackgroundGlycosylation of immunoglobin G in tumors: Function, regulation and clinical implications
Yang, S., Cui, M., Liu, Q., & Liao, Q. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215902 · Cited by 17
Ishitsuka, K., Murahashi, M., Katsuya, H., Mogi, A., Masaki, M., Kawai, C., Goto, T., Ishizu, M., Ikari, Y., Takamatsu, Y., et al. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1811-3 · Cited by 15
An integrated approach to analyze EG2-hFc monoclonal antibody N-glycosylation by MALDI-MS
Bodnar, E. D., Nascimento, T., Girard, L., Komatsu, E., Lopez, P. G., de Oliveira, A. G. G., Roy, R., Smythe, T. A., Zogbi, Y., Spearman, M. A., et al. (2015) · Canadian Journal of Chemistry · doi:10.1139/cjc-2015-0061 · Cited by 15
Les anticorps : mieux les connaître pour mieux s’en servir
Abès, R., Dutertre, C., & Teillaud, J. (2009) · médecine/sciences · doi:10.1051/medsci/200925121011 · Cited by 21
Perdivara, I., Deterding, L. J., Cozma, C., Tomer, K. B., & Przybylski, M. (2009) · Glycobiology · doi:10.1093/glycob/cwp038 · Cited by 16
Yamada, T., Kanda, Y., Takayama, M., Hashimoto, A., Sugihara, T., Satoh-Kubota, A., Suzuki-Takanami, E., Yano, K., Iida, S., & Satoh, M. (2016) · Glycobiology · doi:10.1093/glycob/cww001 · Cited by 14
Self-citationHuang, T., Chen, X., Gu, H., Zhao, C., Liu, X., Yan, M., Deng, X., Zhang, Z., & Gu, J. (2016) · Oncotarget · doi:10.18632/oncotarget.9085 · Cited by 16
Nakajima, T., Okayama, H., Ashizawa, M., Noda, M., Aoto, K., Saito, M., Monma, T., Ohki, S., Shibata, M., Takenoshita, S., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.7556 · Cited by 16
“For example, modification of antibodies to increase binding to Fc γ R has been pursued in order to augment ADCC (11,12).”
The pivotal nature of sugars in normal physiology and disease
Alavi, A., & Axford, J. S. (2006) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-005-0247-4 · Cited by 14
Separation of nonfucosylated antibodies with immobilized FcγRIII receptors
Bolton, G., Ackerman, M. E., & Boesch, A. W. (2013) · Biotechnology Progress · doi:10.1002/btpr.1717 · Cited by 14
Mizutani, A., 綱島, 裕., Nishijima, K.-I., Sasamoto, T., Yamada, Y., Kojima, Y., Motono, M., Kojima, J., Inayoshi, Y., Miyake, K., et al. (2011) · Transgenic Research · doi:10.1007/s11248-011-9511-0 · Cited by 14
Yanaka, S., Sakae, Y., Miyanoiri, Y., Yamaguchi, T., Isono, Y., Kondo, S., Iwasaki, M., Onitsuka, M., Yagi, H., & Kato, K. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2505473122 · Cited by 15
“…conversely, removing fucose from the Fc glycan enhances ADCC, a property that has been applied in therapeutic antibody development ( 10 , 18 – 20 ), while serum IgG1 in individuals with severe COVID - 19, exacerbated by cytokine syndrome, tends to exhibit a higher degree of…”
Strohl, W. R. (2011) · Modecular medicine and medicinal · doi:10.1142/9781848166295_0005 · Cited by 14
Metabolic utilization and remodeling of glycan biosynthesis using fucose analogs
Kizuka, Y. (2022) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2022.130243 · Cited by 14
Wójcik, I., Wuhrer, M., Heeringa, P., Stegeman, C. A., Rutgers, A., & Falck, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1214945 · Cited by 14
“Thus, fucosylation may act as a safety switch hampering potentially harmful cellular immune functions (43, 44).”
BackgroundIn silico evaluation of the role of Fab glycosylation in cetuximab antibody dynamics
Saporiti, S., Bianchi, D., Mariem, O. B., Rossi, M., Guerrini, U., Eberini, I., & Centola, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1429600 · Cited by 14
High-throughput N-glycan analysis in aging and inflammaging: State of the art and future directions
Cindrić, A., Pribić, T., & Lauc, G. (2024) · Seminars in Immunology · doi:10.1016/j.smim.2024.101890 · Cited by 16
Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells
Harada, T., & Ozaki, S. (2014) · BioMed Research International · doi:10.1155/2014/965384 · Cited by 18
Kolios, A. G. A., Lutterotti, A., Kulcsár, Z., Renner, T., Rudiger, A., & Nilsson, J. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108574 · Cited by 13
Structural and Functional Roles of the N-Glycans in Therapeutic Antibodies
Yagi, H., Yanaka, S., & Kato, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819475-1.00044-4 · Cited by 13
Glycosylation States on Intact Proteins Determined by NMR Spectroscopy
Hargett, A. A., Marcella, A. M., Yu, H., Li, C., Orwenyo, J., Battistel, M. D., Wang, L., & Freedberg, D. I. (2021) · Molecules · doi:10.3390/molecules26144308 · Cited by 13
Metadata
- Authors
- Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., Hanai, N., & Shitara, K.
- Affiliations
- Kyowa Kirin (Japan) (JP)
- Corresponding author
- Shitara, Kenya
- ORCID
- Uchida, Kazuhisa
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 278
- Issue
- 5
- Pages
- 3466-3473
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2084136419
- Cited by
- 1,413
- References
- 33
- Citations by year
- 2026: 37 · 2025: 47 · 2024: 55 · 2023: 45 · 2022: 77 · 2021: 78 · 2020: 87 · 2019: 70 · 2018: 83 · 2017: 77 · 2016: 71 · 2015: 72 · 2014: 78 · 2013: 56 · 2012: 67
- FWCI
- 14.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6498 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- antibody-dependent cellular cytotoxicity, fucosylation, bisecting N-acetylglucosamine, galactose, FUT8, alpha-1,6-fucosyltransferase, humanized monoclonal antibody, CHO cell expression, antibody glycosylation, therapeutic antibodies
- MeSH terms
- Acetylglucosamine, Animals, Antibody-Dependent Cell Cytotoxicity, Base Sequence, Carbohydrate Conformation, Carbohydrate Sequence, Cell Line, Chromatography, Affinity, Fucose, Galactose, Cricetinae, Humans, Immunoglobulin G, Molecular Sequence Data, Oligosaccharides, Recombinant Fusion Proteins, Transfection, Polymerase Chain Reaction, CHO Cells, DNA Primers, Lectins, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.